Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | BRAF class 2 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05512208 | Phase II | Defactinib + RO5126766 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) | Recruiting | USA | 0 |
NCT05355701 | Phase I | Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Recruiting | USA | ISR | CAN | 0 |
NCT05538130 | Phase I | PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |
NCT05580770 | Phase Ib/II | BGB3245 + PD-0325901 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT04913285 | Phase I | Binimetinib + Exarafenib Exarafenib | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Recruiting | USA | NLD | FRA | ESP | AUS | 3 |
NCT06270082 | Phase I | IK-595 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Recruiting | USA | 0 |